ProFunds Biotechnology UltraSector Fund Service Class
NASDAQ·Asset Management · Financial Services
$46.58$1.16−2.43%
Market closed·Jul 22 8:00 PM UTC
Loading…
Frequently Asked Questions About BIPSX
What does BIPSX invest in?
This fund's investment strategy involves allocating capital to various financial instruments, carefully selected by its adviser, with the aim of achieving daily returns that align with its stated objectives. It seeks to track a specific index that measures the performance of select companies within the U.S. biotechnology sector of the equity market. Notably, the fund employs a concentrated investment approach, meaning it is not diversified.
What is the expense ratio of BIPSX?
ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) charges an expense ratio of 2.52%. This is the annual fee deducted from fund assets to cover management and operations.
How big is BIPSX?
ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) manages $181.5M in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure — funds below ~$50M are at higher risk of liquidation.
Is BIPSX actively managed or an index fund?
BIPSX is a passive index fund — it tracks a published benchmark by holding the constituents in their published weights. Index funds typically charge low expense ratios (BIPSX's is 2.52%) because there's no security selection cost.
When was BIPSX launched?
ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) launched in June 2000 and is managed by the fund issuer.
How has BIPSX performed?
BIPSX's total return — price change plus reinvested distributions — is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon.
This fund's investment strategy involves allocating capital to various financial instruments, carefully selected by its adviser, with the aim of achieving daily returns that align with its stated objectives. It seeks to track a specific index that measures the performance of select companies within the U.S. biotechnology sector of the equity market. Notably, the fund employs a concentrated investment approach, meaning it is not diversified.
Cost Verdict
Is BIPSX's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.